Lee, J. H., Choi, J., Min, C.-K., Park, S.-S., Jo, J.-C., Lee, Y. J., Kim, J. S., Eom, H.-S., Jung, J., Moon, J. H., Cho, H. J., Lee, M.- won, Yoon, S.-S., Byun, J. M., Lee, J. H., Lee, J.-J., Jung, S.-H., Shin, H.-J., Kim, D. Y., Yi, J. H., Lee, S.-S., Do, Y. R., Yoon, D. H., Cho, H., Lee, W. S., Lee, H. S., Uhm, J., Kim, H. J., Jang, H. R., Kim, S.-H. and Kim, K. (2020) “Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: Results of the multicenter KMMWP2201 study”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2024.285534.